Filtered By:
Source: Circulation
Condition: Heart Attack

This page shows you your search results in order of date. This is page number 13.

Order by Relevance | Date

Total 272 results found since Jan 2013.

Incident Cardiovascular Disease Among Adults with Blood Pressure < 140/90 mm Hg.
Conclusions -While higher BP levels are associated with increased CVD risk, in the modern era, the majority of incident CVD events occur in US adults with SBP/DBP<140/90 mmHg. Although absolute risk and cost-effectiveness should be considered, additional CVD risk reduction measures for adults with SBP/DBP<140/90 mmHg at high risk for CVD may be warranted. PMID: 28634217 [PubMed - as supplied by publisher]
Source: Circulation - June 20, 2017 Category: Cardiology Authors: Tajeu GS, Booth JN, Colantonio LD, Gottesman RF, Howard G, Lackland DT, O'Brien E, Oparil S, Ravenell JE, Safford MM, Seals SR, Shimbo D, Shea S, Spruill TM, Tanner RM, Muntner P Tags: Circulation Source Type: research

Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes: International Insights from the TECOS Trial.
Conclusions -In an international trial population, significant opportunities exist to improve the quality of cardiovascular secondary prevention care among patients with diabetes and CVD, which in turn could lead to reduced risk of downstream cardiovascular events. Clinical Trial Registration -URL: http://www.clinicaltrials.gov. Unique identifier: NCT00790205. PMID: 28626088 [PubMed - as supplied by publisher]
Source: Circulation - June 16, 2017 Category: Cardiology Authors: Pagidipati NJ, Navar AM, Pieper KS, Green JB, Bethel MA, Armstrong PW, Josse RG, McGuire DK, Lokhnygina Y, Cornel JH, Halvorsen S, Strandberg TE, Delibasi T, Holman RR, Peterson ED, TECOS Study Group Tags: Circulation Source Type: research

Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients with Hypertension: The Systolic Blood Pressure Intervention (SPRINT) Trial.
Conclusions -Among patients with hypertension but no diabetes, intensive BP lowering (target systolic BP<120 mmHg), compared with standard BP lowering (target systolic BP<140 mmHg), resulted in lower rates of developing new LVH in those without LVH, and higher rates of regression of LVH in those with existing LVH. This favorable effect on LVH did not explain most of the reduction in CVD events associated with intensive BP lowering in the SPRINT trial. Clinical Trial Registration -URL: ClinicalTrials.gov Unique Identifier: NCT01206062. PMID: 28512184 [PubMed - as supplied by publisher]
Source: Circulation - May 16, 2017 Category: Cardiology Authors: Soliman EZ, Ambrosius WT, Cushman WC, Zhang ZM, Bates JT, Neyra JA, Carson TY, Tamariz L, Ghazi L, Cho ME, Shapiro BP, He J, Fine LJ, Lewis CE, SPRINT Research Study Group Tags: Circulation Source Type: research

Cholesterol Efflux Capacity, HDL Particle Number, and Incident Cardiovascular Events. An Analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).
Conclusions -In JUPITER, cholesterol efflux capacity was associated with incident CVD in individuals on potent statin therapy but not at baseline. For both baseline and on-statin analyses, HDL particle number was the strongest of four HDL-related biomarkers as an inverse predictor of incident events and biomarker of residual risk. Clinical Trial Registration -URL: http://www.clinicaltrials.gov. Unique identifier: NCT00239681. PMID: 28450350 [PubMed - as supplied by publisher]
Source: Circulation - April 27, 2017 Category: Cardiology Authors: Khera AV, Demler O, Adelman SJ, Collins HL, Glynn RJ, Ridker PM, Rader DJ, Mora S Tags: Circulation Source Type: research

Range of Risk Factor Levels: Control, Mortality, and Cardiovascular Outcomes in Type 1 Diabetes Mellitus.
CONCLUSIONS: A steep-graded association exists between decreasing number of cardiovascular risk factors at target and major adverse cardiovascular outcomes among patients with T1DM. However, risks for all outcomes were numerically higher for patients with T1DM compared with controls, even when all risk factors were at target, with risk for acute myocardial infarction and heart failure hospitalization statistically significantly higher. PMID: 28416524 [PubMed - in process]
Source: Circulation - April 18, 2017 Category: Cardiology Authors: Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson AM, Miftaraj M, McGuire DK, Sattar N, Rosengren A, Gudbjörnsdottir S Tags: Circulation Source Type: research

A Multimodality Strategy for Cardiovascular Risk Assessment: Performance in Two Population-Based Cohorts.
Conclusions -Among adults without known CVD, a novel multimodality testing strategy using ECG-LVH, CAC, NT-proBNP, hs-cTnT and hs-CRP significantly improved global CVD and ASCVD risk assessment. PMID: 28360032 [PubMed - as supplied by publisher]
Source: Circulation - March 30, 2017 Category: Cardiology Authors: de Lemos JA, Ayers CR, Levine BD, deFilippi CR, Wang TJ, Hundley WG, Berry JD, Seliger SL, McGuire DK, Ouyang P, Drazner MH, Budoff MJ, Greenland P, Ballantyne CM, Khera A Tags: Circulation Source Type: research

Transcatheter Treatment of Severe Tricuspid Regurgitation with the Edge-to-Edge: MitraClip Technique.
Conclusions -Transcatheter treatment of TR with the MitraClip system seems to be safe and feasible in this cohort of preselected patients. Initial efficacy analysis showed encouraging reduction of TR, which may potentially result in improved clinical outcomes. PMID: 28336788 [PubMed - as supplied by publisher]
Source: Circulation - March 23, 2017 Category: Cardiology Authors: Nickenig G, Kowalski M, Hausleiter J, Braun D, Schofer J, Yzeiraj E, Rudolph V, Friedrichs K, Maisano F, Taramasso M, Fam NP, Bianchi G, Bedogni F, Denti P, Alfieri O, Latib A, Colombo A, Hammerstingl C, Schueler R Tags: Circulation Source Type: research

Cardiac Outcomes After Ischemic Stroke or TIA: Effects of Pioglitazone in Patients with Insulin Resistance Without Diabetes.
Conclusions -Among patients with insulin resistance without diabetes, pioglitazone reduced the risk for acute coronary syndromes after a recent cerebrovascular event. Pioglitazone appeared to have its most prominent effect in preventing spontaneous type 1 MI's. Clinical Trial Registration - https://clinicaltrials.gov Unique Identifier: NCT00091949 US Food & Drug Administration IND: 64,622; EudraCT#2008-005546-23. PMID: 28246237 [PubMed - as supplied by publisher]
Source: Circulation - February 27, 2017 Category: Cardiology Authors: Young LH, Viscoli CM, Curtis JP, Inzucchi SE, Schwartz GG, Lovejoy AM, Furie KL, Gorman MJ, Conwit RA, Abbott JD, Jacoby DL, Kolansky DM, Pfau SE, Ling FS, Kernan WN, IRIS Investigators Tags: Circulation Source Type: research

Medical Therapy for Secondary Prevention and Long-Term Outcome in Patients with Myocardial Infarction with Non-Obstructive Coronary Artery (MINOCA) Disease.
Conclusions -The results indicate long-term beneficial effects on outcome in patients with MINOCA of treatment with statins and ACEI/ARBs, a trend toward a positive effect of beta-blocker treatment, and a neutral effect of DAPT. Properly powered randomized clinical trials to confirm these results are warranted. PMID: 28179398 [PubMed - as supplied by publisher]
Source: Circulation - February 7, 2017 Category: Cardiology Authors: Lindahl B, Baron T, Erlinge D, Hadziosmanovic N, Nordenskjöld AM, Gard A, Jernberg T Tags: Circulation Source Type: research

Preterm Delivery and Maternal Cardiovascular Disease in Young and Middle-Aged Adult Women.
CONCLUSIONS: Preterm delivery is independently predictive of CVD and may be useful for CVD prevention efforts. Because only a modest proportion of the preterm-CVD association was accounted for by development of conventional CVD risk factors, further research may identify additional pathways. PMID: 28153993 [PubMed - in process]
Source: Circulation - February 6, 2017 Category: Cardiology Authors: Tanz LJ, Stuart JJ, Williams PL, Rimm EB, Missmer SA, Rexrode KM, Mukamal KJ, Rich-Edwards JW Tags: Circulation Source Type: research

Thrombus Aspiration in ST Elevation Myocardial Infarction: An Individual Patient Meta-analysis.
CONCLUSIONS: -Routine thrombus aspiration during STEMI PCI did not improve clinical outcomes. In the high thrombus burden subgroup the trends toward reduced CV death and increased stroke or TIA provide a rationale for future trials of improved thrombus aspiration technologies in this high-risk subgroup. Clinical Trial Registration-ClinicalTrials.gov identifier NCT02552407, PROSPERO CRD42015025936. PMID: 27941066 [PubMed - as supplied by publisher]
Source: Circulation - December 8, 2016 Category: Cardiology Authors: Jolly SS, James SK, Džavík V, Cairns JA, Mahmoud KD, Zijlstra F, Yusuf S, Olivecrona GK, Renlund H, Gao P, Lagerqvist B, Alazzoni A, Kedev S, Stankovic G, Meeks B, Frøbert O Tags: Circulation Source Type: research

Incident Type 2 Myocardial Infarction in a Cohort of Patients Undergoing Coronary or Peripheral Arterial Angiography.
CONCLUSIONS: -T2MI is common and associated with poor prognosis. Studies evaluating treatment strategies for management of T2MI are needed.Clinical Trial Registration -https://clinicaltrials.gov/ct2/show/NCT00842868, Clinical Trials.Gov # NCT00842868. PMID: 27881568 [PubMed - as supplied by publisher]
Source: Circulation - November 20, 2016 Category: Cardiology Authors: Gaggin HK, Liu Y, Lyass A, van Kimmenade RR, Motiwala SR, Kelly N, Mallick A, Gandhi PU, Ibrahim NE, Simon M, Bhardwaj A, Belcher A, Harisiades JE, Massaro JM, D'Agostino RB, Januzzi JL Tags: Circulation Source Type: research

Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population.
CONCLUSIONS: -Among patients with vascular disease, there is very substantial variation in estimated 10-year risk of recurrent vascular events. If all modifiable risk factors were at guideline- recommended targets, half of the patients would have a 10-year risk of <10%. These data suggest that even with optimal treatment, many patients with vascular disease will remain at >20% and even >30% 10-year risk, clearly delineating an area of substantial unmet medical need. PMID: 27682883 [PubMed - as supplied by publisher]
Source: Circulation - September 27, 2016 Category: Cardiology Authors: Kaasenbrood L, Boekholdt SM, van der Graaf Y, Ray KK, Peters RJ, Kastelein JJ, Amarenco P, LaRosa JC, Cramer MJ, Westerink J, Kappelle LJ, de Borst GJ, Visseren FL Tags: Circulation Source Type: research

Prasugrel versus Ticagrelor in Patients with Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study.
CONCLUSION: This head-to-head comparison of prasugrel and ticagrelor does not support the hypothesis that one is more effective or safer than the other in preventing ischemic and bleeding events in the acute phase of myocardial infarction treated with primary PCI strategy. The observed rates of major outcomes were similar, although with broad confidence intervals around the estimates. These interesting observations need to be confirmed in a larger trial. CLINICAL TRIAL REGISTRATION: URL: http://www.ClinicalTrials.gov. Unique identifier: NCT02808767. PMID: 27576777 [PubMed - as supplied by publisher]
Source: Circulation - August 29, 2016 Category: Cardiology Authors: Motovska Z, Hlinomaz O, Miklik R, Hromadka M, Varvarovsky I, Dusek J, Knot J, Jarkovsky J, Kala P, Rokyta R, Tousek F, Kramarikova P, Majtan B, Simek S, Branny M, Mrozek J, Cervinka P, Ostransky J, Widimsky P Tags: Circulation Source Type: research

Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54).
CONCLUSIONS: High-risk patients with prior myocardial infarction are at risk for stroke, approximately one-third of which are fatal or lead to moderate-to-severe disability. The addition of ticagrelor 60 mg twice daily significantly reduced this risk without an excess of hemorrhagic stroke but with more major bleeding. In high-risk patients with coronary disease, more intensive antiplatelet therapy should be considered not only to reduce the risk of coronary events, but also of stroke. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique Identifier: NCT01225562. PMID: 27576775 [PubMed - as supplied by publisher]
Source: Circulation - August 29, 2016 Category: Cardiology Authors: Bonaca MP, Goto S, Bhatt DL, Steg PG, Storey RF, Cohen M, Goodrich E, Mauri L, Ophuis TO, Ruda M, Spinar J, Seung KB, Hu DY, Dalby AJ, Jensen EC, Held P, Morrow DA, Braunwald E, Sabatine MS Tags: Circulation Source Type: research